Demetrix Begins Demo Scale Production Of CBG
Demetrix Inc., a biotechnology company that makes cannabinoids, has commenced 15,000-liter demo-scale fermentation production of the rare cannabinoid cannibigerol (CBG). The company’s demo-scale production follows the successful completion of numerous pilot-scale fermentations and is a critical milestone towards the commercialization of rare cannabinoids for a range of safe, effective and legal health and wellness products, from pharmaceuticals to skincare.
While there has been tremendous interest in common cannabinoids like THC and CBD in recent years, little is known about the more than 100 additional cannabinoids found in the cannabis and hemp plants. THC and CBD can each represent upwards of 30% of the plant’s dry flower, but rare cannabinoids like CBG are only present in minuscule quantities below 1%, making them hard to access and study, despite their potential to improve people’s lives. Demetrix has created a fermentation technology platform that allows the company to produce high-purity rare cannabinoids faster, more sustainably, and more affordably than traditional methods. The company has operated at an unprecedented velocity, going from initial technology development to demo-scale production in just three years.
Demetrix is a venture-backed company that has secured $61 million dollars to date. The company’s team is made up of industry veterans with a history of innovation and bringing fermentation products to market, with experts in R&D, production, regulation, and commercialization.
To learn more about Demetrix, visit www.demetrixbio.com.
